Thyroid cancer (TC) is the eighth most frequently diagnosed cancer worldwide with a rising
incidence in the past 20 years. Surgery is the primary strategy of therapy for patients with …

Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant
rise in the number of TC cases has been observed for the past few decades. TCs are one of …

Background: Sorafenib and lenvatinib have been widely adopted to treat radioactive iodine
(RAI)-refractory differentiated thyroid carcinoma (DTC). However, limited data exist …

Objective Thyroglobulin measurement is the cornerstone of modern management of
differentiated thyroid cancer, with clinical decisions on treatment and follow-up based on the …

Background: The management of patients with locally advanced or metastatic differentiated
thyroid cancer (DTC) that is refractory to radioiodine (RAI) remains a therapeutic challenge …

Simple Summary Tyrosine kinase inhibitors are an effective and promising therapy in the
treatment of advanced differentiated medullary thyroid cancers. The prevention and …

Context Radioiodine refractory differentiated thyroid cancer (RAIR-DTC) has been a global
challenge due to its poor prognosis and limited treatment options. Objective We report here …

Background Hypertension (HTN) is the most frequent adverse event during treatment with
lenvatinib (LEN), but data on its best management are limited. Aim The objective of this …

Over the past decade, the prognosis of advanced thyroid cancer (TC) patients has
dramatically improved thanks to the introduction of tyrosine kinase inhibitors (TKIs). Despite …

Purpose The efficacy of lenvatinib for advanced and progressive radioactive iodine
refractory differentiated thyroid cancer is well established. Herein, we retrospectively …